Healthcare Industry News: allergic rhinitis
News Release - August 7, 2006
Inspire Announces Vice President AppointmentsDURHAM, N.C.--(HSMN NewsFeed)--Aug. 7, 2006--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH ) announced today the hiring of two new Vice Presidents, Bart J. Dunn as Vice President, Business Development and Raymond W. Hines as Vice President, Associate General Counsel.
"We are excited to welcome Bart and Ray, both highly experienced and successful professionals, to our team," stated Christy L. Shaffer, Ph.D., President and CEO of Inspire. "We are confident that their expertise will serve Inspire well as we advance our product candidates, continue to support commercialization of our marketed products and pursue strategic in-licensing and out-licensing opportunities."
Mr. Dunn joins Inspire after a 16-year career at Pfizer Inc., most recently serving as Director of Business Development in the Corporate Strategic Planning group. In this capacity, he led multi-disciplinary teams through the evaluation, recommendation, structuring and execution of strategic acquisitions, alliances, product/technology licensing and divestitures. Mr. Dunn received an M.B.A. in Pharmaceutical Marketing from Saint Joseph's University and a B.B.A. in Accounting from Pace University. He is a Certified Public Accountant, licensed in the state of New York.
Mr. Hines spent five years as Vice President & Legal Counsel of Business Development at King Pharmaceuticals, Inc. before joining Inspire. At King, he was lead attorney on business development transactions, including mergers, acquisitions, collaborations, in-licensings, and divestitures. Prior to King, Mr. Hines was Senior Counsel at GlaxoSmithKline in North Carolina and Partner at Ward and Smith, P.A. He received a J.D. with honors from the University of Kentucky College of Law and a B.A. from Davidson College.
The company also announced the promotion of Jenny R. Kobin from Senior Director, Investor Relations to Vice President of Investor Relations and Corporate Communications. Ms. Kobin has been with Inspire since August of 2004 and has more than 15 years of experience in investor relations and corporate communications.
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis, allergic rhinitis and acute cardiac care. Inspire's U.S. specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. For more information, visit www.inspirepharm.com.
The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.
Source: Inspire Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.